[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019008482A - Tratamiento medico que comprende administracion enteral de edaravona. - Google Patents

Tratamiento medico que comprende administracion enteral de edaravona.

Info

Publication number
MX2019008482A
MX2019008482A MX2019008482A MX2019008482A MX2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A
Authority
MX
Mexico
Prior art keywords
edaravone
composition
liquid
enteral administration
pharmaceutical composition
Prior art date
Application number
MX2019008482A
Other languages
English (en)
Other versions
MX390101B (es
Inventor
Hyke Moolenaar Sytske
Original Assignee
Treeway Tw001 B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeway Tw001 B V filed Critical Treeway Tw001 B V
Publication of MX2019008482A publication Critical patent/MX2019008482A/es
Publication of MX390101B publication Critical patent/MX390101B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica sólida dispersable en agua para su uso en el tratamiento de una enfermedad, comprendiendo dicho tratamiento la dispersión de la composición farmacéutica en un líquido acuoso para producir un líquido administrable por vía enteral que contiene al menos 0,5 gramos de composición farmacéutica y al menos 0,3 g/l de edaravona, seguido de la administración enteral de un líquido administrable por vía enteral a un paciente humano en una cantidad que proporciona una dosis de 30-300 mg de edaravona, comprendiendo dicha composición farmacéutica: • un 2-50 % en peso de 3-metil-1-fenil-2-pirazolin-5-ona (edaravona); y • un 3-50 % en peso de un agente alcalinizante soluble. Esta composición sólida que contiene edaravona se puede dispersar de forma sencilla en un líquido acuoso para preparar una solución acuosa de edaravona que se puede ingerir por parte del paciente. La composición sólida de la presente invención ofrece la ventaja de que edaravona se disuelve muy rápidamente cuando se introduce la composición en agua y de que el líquido administrable por vía enteral obtenido de este modo tiene elevada biodisponibilidad oral.
MX2019008482A 2017-01-17 2017-07-06 Tratamiento medico que comprende administracion enteral de edaravona MX390101B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151741 2017-01-17
PCT/EP2017/067005 WO2018133957A1 (en) 2017-01-17 2017-07-06 Medical treatment comprising enteral administration of edaravone

Publications (2)

Publication Number Publication Date
MX2019008482A true MX2019008482A (es) 2019-11-11
MX390101B MX390101B (es) 2025-03-20

Family

ID=57850912

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008482A MX390101B (es) 2017-01-17 2017-07-06 Tratamiento medico que comprende administracion enteral de edaravona

Country Status (12)

Country Link
US (1) US10966960B2 (es)
EP (1) EP3570819B1 (es)
JP (1) JP6898027B2 (es)
AU (1) AU2017394478B2 (es)
BR (1) BR112019014712A2 (es)
CA (1) CA3050031A1 (es)
DK (1) DK3570819T3 (es)
ES (1) ES2868955T3 (es)
MX (1) MX390101B (es)
PL (1) PL3570819T3 (es)
PT (1) PT3570819T (es)
WO (1) WO2018133957A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2868955T3 (es) 2017-01-17 2021-10-22 Treeway Tw001 B V Tratamiento médico que comprende la administración enteral de edaravona
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
MX2021005144A (es) 2018-11-02 2021-07-15 Mitsubishi Tanabe Pharma Corp Suspension de edaravona para administracion oral.
WO2024172852A1 (en) 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405637B1 (en) 2000-10-24 2005-09-07 Mitsubishi Pharma Corporation Remedies for amyotrophic lateral sclerosis (als)
IS7278A (is) 2001-11-26 2003-05-27 Merlyn Associates, Inc. Barkaslanga með stefnustjórnanlegum enda og stöðuhaldandi búnaði
CN1241565C (zh) * 2003-04-16 2006-02-15 浙江震元制药有限公司 依达拉奉药物组合物及制备
CN100358520C (zh) 2003-09-11 2008-01-02 彭建华 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法
EP1714960B1 (en) 2004-02-09 2018-03-28 Mitsubishi Tanabe Pharma Corporation Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
US20140228420A1 (en) 2011-09-05 2014-08-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
CN103251554A (zh) 2013-06-06 2013-08-21 南京亿华药业有限公司 一种稳定的依达拉奉注射液及其制备方法
CN109125261B (zh) 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
ES2868955T3 (es) 2017-01-17 2021-10-22 Treeway Tw001 B V Tratamiento médico que comprende la administración enteral de edaravona
AU2018209155B2 (en) 2017-01-17 2023-11-30 Treeway Tw001 B.V. Treatment comprising oral or gastric administration of edaravone
EP3648760A1 (en) 2017-07-06 2020-05-13 Treeway TW001 B.V. Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders

Also Published As

Publication number Publication date
EP3570819B1 (en) 2021-03-03
BR112019014712A2 (pt) 2020-02-18
AU2017394478A1 (en) 2019-08-01
CA3050031A1 (en) 2018-07-26
PL3570819T3 (pl) 2021-10-25
ES2868955T3 (es) 2021-10-22
PT3570819T (pt) 2021-04-20
EP3570819A1 (en) 2019-11-27
JP6898027B2 (ja) 2021-07-07
WO2018133957A1 (en) 2018-07-26
JP2020506958A (ja) 2020-03-05
US20190328711A1 (en) 2019-10-31
MX390101B (es) 2025-03-20
DK3570819T3 (da) 2021-04-06
AU2017394478B2 (en) 2023-07-20
US10966960B2 (en) 2021-04-06

Similar Documents

Publication Publication Date Title
HRP20240485T1 (hr) Pripravci glp-1 i njihova upotreba
MX2019008482A (es) Tratamiento medico que comprende administracion enteral de edaravona.
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR112015004244A2 (pt) composição médica oralmente administrada
BR112021021904A2 (pt) Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível
ES2834985T3 (es) Composición que contiene cineol para administración nasal
PE20151592A1 (es) Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
GB2477590A (en) A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2019008489A (es) Tratamiento que comprende la administracion oral o gastrica de edaravona.
CN103298464A (zh) 复方组合物
JP2017105861A5 (es)
ME02474B (me) Terapijski režimi
ES2643167T3 (es) Procedimiento de producción y uso de un copolímero de carboximetilcelulosa sódica y gosipol
BR112018016287A2 (pt) sistema de perfusão, método para administrar diretamente a um paciente em necessidade do mesmo uma dose de um fármaco antineoplásico e recipiente de perfusão
CL2013002829A1 (es) Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
Maldonado et al. Update on Emerging Infections: news from the Centers for Disease Control and Prevention. Update to the CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections